Pharmaceuticals News and Research

RSS

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Valeant purchases QLT’s Visudyne

Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.

24 Sep 2012

Sleep medicine and research: an interview with James K. Walsh

There are a variety of sleep medicines. I am going to refer to what are commonly described as hypnotics or sleeping pills. Sleeping pills have been around for a long time.

24 Sep 2012

SAMHSA to unveil results of 2011 National Survey on Drug Use and Health

The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2011) National Survey on Drug Use and Health (NSDUH) at a press conference on Monday, September 24, 2012.

24 Sep 2012

FDA approves Mylan's ANDA for generic Antivert

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg.

21 Sep 2012

Arthroplasty wound complications linked to oral anticoagulant use

Multicenter research suggests that recovery from hip or knee arthroplasty may be significantly affected by choice of pharmaceutical thromboprophylaxis.

21 Sep 2012

Glucocorticoids can thwart androgen receptor activity and regulate fat storage

In the body's ongoing effort to maintain a healthy weight, an arsenal of cellular proteins called androgen receptors is critical for blocking fat accumulation. Now researchers reporting in the September issue of the Cell Press Journal Chemistry & Biology have discovered that naturally occurring steroids called glucocorticoids can thwart the receptors' activity, ultimately encouraging fat buildup.

21 Sep 2012

Drug co. execs say cost-containment pressures undermine medical innovation

Pressure from governments to lower drug prices risks undermining medical innovation, Bayer AG's chief executive said on Wednesday, echoing complaints of other drug company executives. Speaking at the Boston College Chief Executives' Club, Marijn Dekkers said there was "tremendous pressure" on drugmakers to lower prices.

21 Sep 2012

State roundup: HCA fined for kickbacks; Minn. rural health care investigation

The Hospital Corporation of America will pay $16.5 million to settle claims that its subsidiaries had paid a diagnostics firm for referrals, violating federal anti-kickback rules, the Justice Department announced Wednesday. HCA subsidiary Parkridge Medical Center and HCA Physician Services, both provided "financial benefits" to a physician group, Diagnostic Associates of Chattanooga, for referrals to the HCA facilities.

21 Sep 2012

Study identifies factors that contribute to solid stress within tumors

It's a high-pressure environment within solid tumors. Abnormal blood and lymphatic vessels cause fluids to accumulate, and the uncontrolled proliferation of cancer cells within limited space leads to the buildup of what is called solid stress.

21 Sep 2012

FDA approves Acton’s AEROSPAN sNDA to treat asthma

Acton Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for AEROSPAN (flunisolide HFA, 80 mcg) Inhalation Aerosol, a hydrofluoroalkane (HFA) orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients 6 years of age and older.

21 Sep 2012

Data from Navidea’s Lymphoseek Phase 3 studies on solid tumors to be presented at ESSO

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.

21 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

AyoxxA Biosystems closes 2.6M Euro Series A financing round

AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

20 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

BGI Tech achieves whole exome sequencing analysis of total degraded DNA from FFPE samples

BGI Tech Solutions Co., Ltd., a subsidiary company of BGI, announced today that they have achieved whole exome sequencing analysis of total degraded DNA as low as 200 ng from formalin fixed paraffin embedded (FFPE) samples.

19 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Roundup: Mont. settlement money to pay for uninsured's prescription drugs; Physician assistants' role in Mass.; Atlanta to cut worker premiums

The Montana attorney general's office says nearly $1 million collected in drug company settlements will be used to help pay for prescription medicine for people who are uninsured and underinsured. Attorney General Steve Bullock said in a statement Thursday the money came from settlements dating back to 2010 with four drug companies accused of inflating the wholesale prices of drugs paid by Medicare and Medicaid.

18 Sep 2012